CPI-300 (University of Chicago)

**CPI-300** is an investigational antitumor nanomedicine developed by Coordination Pharmaceuticals. It is a nanoscale coordination polymer nanoparticle formulation designed to co-deliver two undisclosed new chemical entities to tumors following intravenous infusion. The identities, molecular targets, and precise mechanisms of the two active agents have not been publicly disclosed. CPI-300 entered a first-in-human Phase 1 dose-escalation study in patients with advanced solid tumors to assess safety, tolerability, pharmacokinetics, maximum tolerated dose, and preliminary antitumor activity. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nanoparticle-formulation-cpi-300))

Other names

nanoparticle formulation CPI-300nanoscale coordination polymer-based formulation CPI-300NCP platform-based CPI-300